car t cells

Cell therapyexperimental

Clinical trial activity

10 trials · 11 clinical orgs · 0 marketing orgs

Phase 1
8
Phase 2
3
Phase 3
1
Phase 4
0

Earliest trial started Apr 1, 2017 (NCT03068416)

Timeline

2010s

  1. Jan 1, 2017

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2017

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2025

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • car t cells

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07103668Phase 3Aug 6, 2025Government of China
NCT07053670Phase 1Jul 9, 2025Huazhong University of Science and Technology
NCT07032324Phase 1Jul 8, 2025Zhejiang University
NCT06822868Phase 1Feb 10, 2025Government of China
NCT06734871Phase 1Dec 26, 2024Huazhong University of Science and Technology
NCT05089266Phase 1Nov 30, 2021NO.17 Panjiayuan Nanli, Shanghai Cell Therapy Group Co.,Ltd
NCT04577326Phase 1Sep 30, 2020Atara Biotherapeutics, Memorial Sloan-Kettering Cancer Center
NCT03271632Phase 1/Phase 2 (Phase 2)Jul 15, 2017Shenzhen Geno-Immune Medical Institute
NCT02917083Phase 1May 8, 2017Baylor University, Methodist Cancer Center, Houston, Texas
NCT03068416Phase 2Apr 1, 2017Uppsala University
Showing 10 of 10 trials
Page 1 / 1

Organizations

Research & Development (11)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Government of ChinaGovernment2222025
Huazhong University of Science and TechnologyAcademic/Hospital2212024
Atara BiotherapeuticsFor profit1012020
Baylor UniversityAcademic/Hospital1112017
Memorial Sloan-Kettering Cancer CenterAcademic/Hospital1112020
Methodist Cancer Center, Houston, TexasAcademic/Hospital1012017
NO.17 Panjiayuan NanliAcademic/Hospital1012021
Shanghai Cell Therapy Group Co.,LtdFor profit1112021
Shenzhen Geno-Immune Medical InstituteAcademic/Hospital1112017
Uppsala UniversityAcademic/Hospital1112017
Zhejiang UniversityAcademic/Hospital1112025
11 organizations
Page 1 / 1